Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/55112 |
Resumo: | Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Wellcome Trust. "Fazer o bem faz bem” program. Brazilian National Research Council. |
id |
CRUZ_5f72feb2a6008330ee73420bca3da94d |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/55112 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Florentino, Pilar T. VAlves, Flávia J. OSilva, Thiago CerqueiraOliveira, Vinicius de AraújoJúnior, Juracy B. S.Jantsch, Adelson GPenna, Gerson OBoaventura, VivianeWerneck, Guilherme LRodrigues, Laura CPearce, NeilBarral Netto, ManoelBarreto, Mauricio LPaixão, Enny S2022-10-11T17:49:17Z2022-10-11T17:49:17Z2022FLORENTINO, Pilar T. V. et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nature Communications, v. 13, n.1, p. 1-5, 2022.2041-1723https://www.arca.fiocruz.br/handle/icict/5511210.1038/s41467-022-32524-5Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Wellcome Trust. "Fazer o bem faz bem” program. Brazilian National Research Council.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil / Universidade de São Paulo. Instituto de Ciências Biomédicas. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.Universidade Federal da Bahia. Instituto de Saúde Pública. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Universidade de Brasília. Centro de Medicina Tropical. Escola de Governo Fiocruz. Brasília, DF, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.Universidade Estadual do Rio de Janeiro. Instituto de Medicina Social. Departamento de Epidemiologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Estudos em Saúde Coletiva. Rio de Janeiro, RJ, Brasil.London School of Hygiene and Tropical Medicine. London, UK.London School of Hygiene and Tropical Medicine. London, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos em Saúde. Salvador, BA, BrasilLondon School of Hygiene and Tropical Medicine. London, UK.Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7-45.4) at ≥14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3-84.5) at ≥14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.engNature ResearchCOVID-19CriançaIsolamento socialvacinaCOVID-19ChildSocial isolationVaccineVaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron periodinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/55112/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALFlorentino, Pilar T. V. - Vaccine effectiveness of CoronaVac.pdfFlorentino, Pilar T. V. - Vaccine effectiveness of CoronaVac.pdfapplication/pdf563537https://www.arca.fiocruz.br/bitstream/icict/55112/2/Florentino%2c%20Pilar%20T.%20V.%20-%20Vaccine%20effectiveness%20of%20CoronaVac.pdfbd2f801ad25f39e1dbc718597c03ff9fMD52icict/551122023-03-15 14:32:50.006oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:32:50Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.en_US.fl_str_mv |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
title |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
spellingShingle |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period Florentino, Pilar T. V COVID-19 Criança Isolamento social vacina COVID-19 Child Social isolation Vaccine |
title_short |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
title_full |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
title_fullStr |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
title_full_unstemmed |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
title_sort |
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period |
author |
Florentino, Pilar T. V |
author_facet |
Florentino, Pilar T. V Alves, Flávia J. O Silva, Thiago Cerqueira Oliveira, Vinicius de Araújo Júnior, Juracy B. S. Jantsch, Adelson G Penna, Gerson O Boaventura, Viviane Werneck, Guilherme L Rodrigues, Laura C Pearce, Neil Barral Netto, Manoel Barreto, Mauricio L Paixão, Enny S |
author_role |
author |
author2 |
Alves, Flávia J. O Silva, Thiago Cerqueira Oliveira, Vinicius de Araújo Júnior, Juracy B. S. Jantsch, Adelson G Penna, Gerson O Boaventura, Viviane Werneck, Guilherme L Rodrigues, Laura C Pearce, Neil Barral Netto, Manoel Barreto, Mauricio L Paixão, Enny S |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Florentino, Pilar T. V Alves, Flávia J. O Silva, Thiago Cerqueira Oliveira, Vinicius de Araújo Júnior, Juracy B. S. Jantsch, Adelson G Penna, Gerson O Boaventura, Viviane Werneck, Guilherme L Rodrigues, Laura C Pearce, Neil Barral Netto, Manoel Barreto, Mauricio L Paixão, Enny S |
dc.subject.other.en_US.fl_str_mv |
COVID-19 Criança Isolamento social vacina |
topic |
COVID-19 Criança Isolamento social vacina COVID-19 Child Social isolation Vaccine |
dc.subject.en.en_US.fl_str_mv |
COVID-19 Child Social isolation Vaccine |
description |
Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Wellcome Trust. "Fazer o bem faz bem” program. Brazilian National Research Council. |
publishDate |
2022 |
dc.date.accessioned.fl_str_mv |
2022-10-11T17:49:17Z |
dc.date.available.fl_str_mv |
2022-10-11T17:49:17Z |
dc.date.issued.fl_str_mv |
2022 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
FLORENTINO, Pilar T. V. et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nature Communications, v. 13, n.1, p. 1-5, 2022. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/55112 |
dc.identifier.issn.en_US.fl_str_mv |
2041-1723 |
dc.identifier.doi.none.fl_str_mv |
10.1038/s41467-022-32524-5 |
identifier_str_mv |
FLORENTINO, Pilar T. V. et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nature Communications, v. 13, n.1, p. 1-5, 2022. 2041-1723 10.1038/s41467-022-32524-5 |
url |
https://www.arca.fiocruz.br/handle/icict/55112 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Nature Research |
publisher.none.fl_str_mv |
Nature Research |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/55112/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/55112/2/Florentino%2c%20Pilar%20T.%20V.%20-%20Vaccine%20effectiveness%20of%20CoronaVac.pdf |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 bd2f801ad25f39e1dbc718597c03ff9f |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009311881756672 |